L-Arginine administration attenuates airway inflammation by altering L-arginine metabolism in an NC/Nga mouse model of asthma

Access this Article

Search this Article

Author(s)

    • Zhang Ran
    • Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
    • Kubo Masayuki
    • Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
    • Murakami Ikuo
    • Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences|Third Institute of New Drug Discovery, Biomedical Innovation, Otsuka Pharmaceutical Co., Ltd.
    • Setiawan Heri
    • Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
    • Takemoto Kei
    • Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
    • Inoue Kiyomi
    • Public Health Care Nursing, Department of Nursing, Faculty of Health Sciences, Kobe Tokiwa University
    • Ogino Keiki
    • Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Abstract

Changes in <span style="font-variant: small-caps;">l</span>-arginine metabolism, including increased arginase levels and decreased nitric oxide production, are involved in the pathophysiology of asthma. In this study, using an intranasal mite-induced NC/Nga mouse model of asthma, we examined whether administration of <span style="font-variant: small-caps;">l</span>-arginine ameliorated airway hyperresponsiveness and inflammation by altering <span style="font-variant: small-caps;">l</span>-arginine metabolism. Experimental asthma was induced in NC/Nga mice via intranasal administration of mite crude extract (50 µg/day) on 5 consecutive days (days 0–4, sensitization) and on day 11 (challenge). Oral administration of <span style="font-variant: small-caps;">l</span>-arginine (250 mg/kg) was performed twice daily on days 5–10 for prevention or on days 11–13 for therapy. On day 14, we evaluated the inflammatory airway response (airway hyperresponsiveness, the number of cells in the bronchoalveolar lavage fluid, and the changes in pathological inflammation of the lung), arginase expression and activity, <span style="font-variant: small-caps;">l</span>-arginine bioavailability, and the concentration of NOx, the end products of nitric oxide. Treatment with <span style="font-variant: small-caps;">l</span>-arginine ameliorated the mite-induced inflammatory airway response. Furthermore, <span style="font-variant: small-caps;">l</span>-arginine administration attenuated the increases in arginase expression and activity and elevated the NOx levels by enhancing <span style="font-variant: small-caps;">l</span>-arginine bioavailability. These findings indicate that <span style="font-variant: small-caps;">l</span>-arginine administration may contribute to the improvement of asthmatic symptoms by altering <span style="font-variant: small-caps;">l</span>-arginine metabolism.

Journal

  • Journal of Clinical Biochemistry and Nutrition

    Journal of Clinical Biochemistry and Nutrition 56(3), 201-207, 2015

    SOCIETY FOR FREE RADICAL RESEARCH JAPAN

Codes

  • NII Article ID (NAID)
    130005068179
  • Text Lang
    ENG
  • ISSN
    0912-0009
  • Data Source
    J-STAGE 
Page Top